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Open access under the ElInterleukin 18 (IL-18) is a cytokine that plays an important role in the Th1 response, by its ability to
induce IFN- c production in T cells and natural killer cells. Functional variants of IL18 gene has been 
reported as associated with type 1 diabetes (T1D). In the present study were analyzed three promoter 
single nucleotide polymorphisms (SNPs), at 656 (rs1946519), 607 (rs1946518) and 137
(rs187238) position, in 181 children and adolescents with T1D and 122 healthy individuals, both from 
metropo litan area of Recife, Northeast of Brazil. T1D patients were stratiﬁed accordin g to the presence 
autoimmune thyroiditis and celiac disease. Allele and genotype frequencies of IL18 SNPs were Hardy–
Weinberg equilibrium in patients and controls. The allele 137G and the haplotype 656G/607C/
137G were more frequent in T1D patients (OR = 1.82 and 1.97, respectively) then in healthy controls.
However, those SNPs were not associated with the age of T1D onset as well as with the insurgence of
AITD and/or CD in concomitant with T1D patients. Our ﬁndings suggest an association between IL18 pro-
moter SNPs and suscepti bility to T1D in Bra zilian patients.
 2013 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction Single nucleotide polymorphis ms (SNPs) located at promote rType 1 diabetes mellitus (T1D) is a complex multifactorial dis- 
order where pancreatic insulin producer beta cells are immunolog- 
ically destroyed through a genetic and environmental interplay [1].
Moreover, during the chronic disease evolution of T1D, some pa- 
tients could develop other organ-speciﬁc autoimmune events 
including the insurgen ce of autoimmune thyroidit is (AITD) and/ 
or celiac disease (CD) [2–4], suggesting a shared pathogen esis 
pathway for these disorders.
The inﬂammatory pathway has an important role in the devel- 
opment and complicati ons of T1D [5]. In inﬂammations events,
several interleukins (ILs) could be produced in order to activate 
speciﬁcs immune components and present itself as a potential fac- 
tor in association to T1D pathogenesis [6–8].
The pro-inﬂammatory interleukin 18 (IL-18) is directly involved 
in the innate and speciﬁc immune response, due to its ability to
activate monocytes, macrophages , natural killer (NK) and in syn- 
ergy with IL-12, to promote Th1 type response [8,9].Rego, S/N, Cidade Universitá-
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sevier OA license.position 607 (dbSNP: rs1946518) and 137 (dbSNP: rs187238)
of IL18 gene (11q22.2–q23.3), involved in the decrease of IL18
expression [10–12], have been studied and associated with the 
developmen t of T1D [11–13]. However , divergent results of associ- 
ation have been found in different populations, being necessary 
replicatio ns studies in population with different genetic 
background .
The aim of this work is to investiga te the association between 
IL18 promote r polymorphis ms, namely-656 (dbSNP: rs1946519),
607 (rs1946518) and 137 (rs187238), and T1D in a population 
from Northeast of Brazil. This genetic association was never per- 
formed in an admixtur e population, such the Brazilian one, addi- 
tionally, we hypothesize that patient carrying the IL18 SNPs
possess a lower risk to the insurgence of AITD and/or CD in con- 
comitance with T1D, since low levels of IL-18 could diminish the 
Th1 response and the production of INF- c.2. Materials and methods 
2.1. Patients 
T1D patients (n = 181) were enrolled and followed up at the 
three major pediatric endocrinolo gy centers of health public 
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Fernando Figueira, Hospital da Restauração and Hospital das Clín-
icas – UFPE). The diagnosis of T1D followed the clinical criteria of
American Diabetes Association [14]. The mean age of T1D patients 
was 13.2 years (SD ± 4.1), with 101/181 (56%) females, a gender ra- 
tio equals to 1.26:1. The average age at the onset of T1D was 
7.3 years (SD ± 3.4) and the mean duration of the disease was 
5.9 years (SD ± 3.8).
2.2. Autoimmune thyroid and celiac disease diagnosis 
Antibodies to thyroperox idase (Anti-TPO) diagnosis were per- 
formed by chemio-lumines cence (Immulite anti-TPO Ab, Diagnos- 
tic products Co., Los Angeles, USA). Patients with positive anti-TPO 
(titer exceedin g 35 IU/ml, accordingly to manufac turer’s sugges- 
tion) were considered as having AITD.
Anti-transgl utaminase antibodies (anti-tTg) were determined 
by using the ELISA Eu-tTG kit (Eurospital, Trieste, Italy) following 
manufactur es instructions. Patients presenting 10 AU (absorbance
units) for anti-tTg antibodies were considered positive and subse- 
quently screened for the presence of HLA DQ2 and/or DQ8 HLA 
haplotypes by using the Eu-DQ kit (Eurospital, Trieste, Italy). After 
gluten-free diet in all CD patients, the tTG autoantib odies levels de- 
clined, remaining under the cutoff value of 7 AU.
The frequency of AITD in the T1D patients (T1D + AIDT + DC)
was 20.9% (38/181), the percentage of patients with CD
(T1D + AIDT DC+) was 5.5% (10/181), while patients characterized 
by both AITD and CD (T1D + AIDT + DC+) were 3.3% (6/181).
2.3. Healthy subjects 
Healthy individuals from the same geographi cal region of pa- 
tients group with no clinical evidence or family history of autoim- 
mune diseases were included as control group. We enrolled 142 
healthy subjects, mean age 21.4 years (SD ± 2.4), 93/142 (65%) fe- 
males, a gender ratio 1.89:1. In the choice of the control popula- 
tion, the presence of any HLA possibly associated with celiac 
disease, AIDT, T1D and a titer exceeding 35 IU/ml for anti-TPO ,
10 AU for anti-tTg and 40 nU/ml for anti-IAA were an exclusion 
criterion.
A free and informed consent from each person responsib le for 
the patient and healthy individuals were obtained. The local ethical 
committee (IMIP number 1717/2010) approved the study.
2.4. DNA extraction 
Genomic DNA was extracted from peripheral whole blood using 
the Wizard genomic DNA puriﬁcation kit (Promega, Madison, MA)
according to the standard laborator y protocols.
2.5. SNP genotyping and haplotypes reconstru ction 
The SNPs 656 C/A (rs1946519), 607 G/T (rs1946518) and 
137 G/C (rs187238) located at promoter region of IL18 gene were 
genotyped using ﬂuorescent allele-speciﬁc probes (TaqMan, Life)
with ABI-7500 Real-Time as platform. Linkage disequilibriu m and 
haplotypes were computed using the Arlequin software (version
3.1) and SNPstats (http://bioinfo.iconcologia.net/SN Pstats ).
2.6. Statistical analysis 
Allele and genotype frequencies of IL18 promoter SNPs were ob- 
tained by direct counting. Fisher’s exact test was used to correlate 
SNPs distribut ion and the increased susceptibility, clinical aspects 
of T1D and Hardy–Weinberg equilibrium were obtained using 
the R program (2005; version 2.1.1; http://www.r-project.org/ ).Kruskal Wallis test was used in the age at diagnoses analyses.
The power test analysis was performed through the GPower (ver-
sion 3.1). Odds Ratio (OR) and 95% Conﬁdence Intervals (CI) were 
also calculated. The p-values < 0.0015 was considered as statisti- 
cally signiﬁcant after Bonferroni correction for multiple tests.3. Results 
In this work we analyzed three functional polymorphi sms,
656 C/A, 607 G/T and 137 G/C, at promoter region of the 
IL18 gene in 181 T1D patients and 122 healthy subjects from the 
metropo litan region of Recife (Brazil). SNPs allele and genotype 
distribut ion are listed in Table 1. Genotype and allele SNPs fre- 
quencies in the studied groups were in Hardy–Weinberg 
equilibriu m.
Thirty-thr ee analyses were done and six statistical differenc es
were found. However, after Bonferroni Multiple Test Correction 
only two associations for the 137 SNP remained statistical ly sig- 
niﬁcant (p > 0.0015). The 137G allele was less frequent in healthy 
subjects than in T1D + AITD  CD (OR = 1.82, p = 0.0015;
95%CI = 1.24–2.69) and when compare d with all T1D + patients 
(p = 0.0001; OR = 1.96 95%CI = 1.37–2.80). In addition, the 137G/
G genotype was also statistically less frequent in healthy individu- 
als than in patients T1D + AITD  CD (p = 0.0005 OR = 4.55 
95%CI = 1.77–12.9) and in T1D+ (p = 0.00004 OR = 5.00 
95%CI = 2.13–12.4).
No association was found with the IL18 promoter polymor- 
phism and the age at diagnosis of T1D.
Eight haplotypes were found in our population as showed in Ta-
ble 2. The haplotypes 656G/607C/137G, 656T/607A/137C
and 656T/607A/137G represent more than 80% of all haplo- 
types in the studied populations , the other ﬁve ones were rare.
All SNPs were in linkage disequilibrium (D0 > 0.8) in all groups,
excluding the 656 and 137 SNPs in the TD1 + AITD + DC + and 
healthy groups (D0 = 0.6).
The haplotype 656G/607C/137G and 656T/607A/137C
were different ially distribut ed in case subjected when compare d
with healthy individuals (p < 0.0000007).4. Discussions 
T1D is an autoimmune disorder resulted by initial inﬁltration of
Th1 and Th2 lymphocy tes in pancreatic islet followed by progres- 
sive destruction of beta-cells [15,16]. The predominance of Th1 re- 
sponse is widely associate d with T1D onset due to a higher 
production of interferon- c (INF-c) [17]. However, genetic studies 
on INF-c listed some rare variants with low phenotypic impact 
[18], suggestin g other genetic approaches on the regulation of
INF-c production by the IL-18 pathway in synergy with IL-12. In
fact, IL-18 was originally named as an INF- c-inducing factor with 
a correlation between genetic SNP at promoter site of IL18 and
INF-c production and T1D developmen t [10].
The 607A and 137C SNPs are known to down-regul ate the 
gene expression of IL18 at the transcriptio nal level by disrupting 
the cAMP-re sponsive element-binding site and by changing the 
H4TF-1 nuclear factor binding at IL18 promoter [10]. Both events 
could inﬂuence, at least in part, the INF- c production.
In the present report, the allele 137G and genotype 137GG
were associated with the susceptibi lity to T1D. In addition, the 
haplotype 656G/607C/137G was more frequent in case sub- 
jects. Both results supported the hypothesis that lower levels of
IL-18 are protective to T1D onset. Several ﬁndings have been sup- 
porting that increased levels of IL-18 are associated with the sus- 
ceptibilit y to T1D. The plasma levels of IL-18 in T1D patients are 
increased in subclinical stage and involved with disease 
Table 1
Interleukin 18 polymorphism s genotypes and allele frequencies of diabetes mellit us type 1 patients stratiﬁed according to the insurgence of autoimmune thyroid (AITD) and 
celiac disease (CD).
T1D + AITD + CD+ T1D + AITD + CD T1D + AITD  CD+ T1D + AITD  CD T1D+ Healthy 
n = 6 (%) n = 38 (%) n = 10 (%) n = 127 (%) n = 181 (%) n = 122 (%)
656 G 8 (67) 40 (53) 13 (65) 153 (60) 214 (59) 122 (50)
T 4 (33) 36 (47) 7 (35) 101 (40) 148 (41) 122 (50)
G/G 3 (50) 9 (24) 5 (50) 42 (33) 59 (33) 29 (24)
G/T 2 (33) 22 (58) 3 (30) 69 (54) 96 (53) 64 (52)
T/T 1 (17) 7 (18) 2 (20) 16 (13) 26 (14) 29 (24)
607 C 7 (58) 40 (53) 15 (75) 146 (57) 208 (57) 131 (54)
A 5 (42) 36 (47) 5 (25) 108 (43) 154 (43) 113 (46)
C/C 2 (33) 9 (24) 6 (60) 39 (31) 56 (31) 34 (28)
C/A 3 (50) 22 (58) 3 (30) 68 (54) 96 (53) 63 (52)
A/A 1 (17) 7 (18) 1 (10) 20 (16) 29 (16) 25 (20)
137 G 8 (67) 55 (72) 18 (90) 178 (70) 259 (72) 137 (56)
C 4 (33) 21 (28) 2 (10) 76 (30) 103 (28) 107 (44)
G/G 3 (50) 19 (50) 8 (80) 59 (46) 89 (49) 40 (33)
G/C 2 (33) 17 (45) 2 (20) 60 (47) 81 (45) 57 (47)
C/C 1 (17) 2 (5) 0 (0) 8 (6) 11 (6) 25 (20)
Associations according to SNP position:
Comparison Associated allele Associated genotype 
656 T1D + AITD  CD vs healthy T: p = 0.02 OR = 0.66 95%CI = 0.45–0.95 T/T: p = 0.02 OR = 0.38 95%CI = 0.16–0.88
T1D + vs healthy T: p = 0.03 OR = 0.69 95%CI = 0.49–0.97 T/T: p = 0.02 OR = 0.44 95%CI = 0.20–0.93
137 T1D + AITD + CD vs healthy G: p = 0.01 OR = 2.04 95%CI = 1.13–3.78 G/G: p = 0.01 OR = 5.83 95%CI = 1.23–55.9
T1D + AITD  CD + vs healthy G: p = 0.003 OR = 6.99 95%CI = 1.61–63.5 G/G: p = 0.017 OR = 5.61 95%CI = 1.04–56.93
T1D + AIDT  CD vs healthy G: p = 0.0015 OR = 1.82 95%CI = 1.24–2.69 G/G: p = 0.00051 OR = 4.55 95%CI = 1.77–12.9
T1D + vs healthy G: p = 0.00012 OR = 1.96 95%CI = 1.37–2.80 G/G: p = 0.00004 OR = 5.00 95%CI = 2.13–12.4
Table 2
The haplotype distribution of interleuk in 18 polymorphism s, at -656/-607/-137 promoter position, in diabetes mellitus type 1 patients stratiﬁed according to the insurgence of
autoimmune thyroid (AITD) and celiac disease (CD).
Haplotypes TD1 + AITD + CD+ TD1 + AITD + CD TD1 + AITD  CD+ TD1 + AITD  CD TD1+ Healthy 
n = 12 (%) n = 76 (%) n = 20 (%) n = 254 (%) n = 362 (%) n = 244 (%)
656G/607C/137G 7 (58.4) 37 (48.7) 13 (65) 140 (55) 195 (54) 95 (38.9)
656T/607A/137C 3 (25) 20 (26.3) 2 (10) 61 (24) 87 (24) 84 (34.4)
656T/607A/137G 1 (8.3) 12 (15.8) 3 (15) 33 (13) 51 (14) 19 (7.8)
Rare haplotypes 1 (8.3) 7 (9.2) 2 (10) 20 (8) 29 (8) 46 (18.9)
Associations found:
Comparison Haplotype 
656T/607A/137C 656G/607C/137G 
T1D + AITD  DC + vs healthy OR = 1 p = 0.01 OR = 5.70 IC95%1.23–53.5
T1D + AITD  DC vs healthy OR = 1 p = 0.0010 OR = 2.02 IC95% 1.3–3.15
T1D + vs healthy OR = 1 p = 0.0005 OR = 1.97 IC95% 1.31–2.97
288 N.A.C. Tavares et al. / Cytokine 62 (2013) 286–289progression [17,19]. Moreove r, NOD mice with IL-18 deﬁciency are 
protected of T1D progression, since they exhibit reduced T cell 
turnover and fewer effectors T cell [11,20].
However, the contributi on of genetic variation at IL18 promoter
on T1D onset remains on debate. Kretowski et al. [11], in a Polish 
population, described that the 137GC genotypes in combination 
with 607AA gene was associated with susceptibility to T1D, but 
noted an increase in the frequency of 137C allele in T1D patients.
In Chinese Han and Japanese populations the 607C alleles and 
607CA genotype, respectivel y, and the haplotypes 607C/
137G were more frequently in T1D patients [12,13]. These data 
are according with the present report.
In contrast, independen t association studies performed in Ira- 
nian, Czech and England populations did not ﬁnd association of
IL18 promote r SNPs with the susceptibi lity to T1D [21–24].
Moreover, a recent meta-analysis study of the SNP 607 CA,
using several autoimm une disorder, reported no correlation with 
diabetes onset [25]. As well no association was found with the 
insurgence of AITD and CD in T1D patients, suggesting that the 
inﬂammatory pathway triggered by IL-18 are not shared in these 
disorder.The pathogenesis of autoimmune diabetes is complex and not 
inﬂuenced only by genetic proﬁle, but environmental factors could 
play an important role. As Dong et al. [12] observed the genetic 
pool diversity and different environm ental conditions might con- 
tribute to achieve opposite results in different populations of IL18
association.
In summary, our results showed an association of the 137G
SNP at promote r of IL18 with the susceptibility to develop T1D in
Brazilian patients. Brazilian individua ls from Northeast who carry 
this allele are more than 1.8 times more susceptible to T1D onset 
(OR = 1.82 95%CI = 1.24–2.69) and almost 2.0 times more if they 
carry the haplotype 656G/607C/137G (OR = 1.97 IC95%
1.31–2.97). However, those SNPs are not involved with the age at
T1D diagnose and the insurgen ce of AITD and/or CD in concomitan t
with T1D patients. It is important to note that after T1D patients’
subgroup ing some subclasses remain very small, presenting wide 
conﬁdence intervals. The a priori power test indicated that accord- 
ing to the SNP frequencies the sample size in each subclass were 
reliable to ensure the statistically signiﬁcant results with power 
up to 95%. However, further robust analysis must be performed 
to increase the numbers of sample and diminish the effect of sam- 
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developmen t and the insurgen ce of others autoimmune disorders.
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